Top advances in esophageal/gastroesophageal junction cancers in 2021
Cet article passe en revue les principales avancées de l'année 2021 en matière de traitement des cancers de l'oesophage ou de la jonction oesogastrique
A review of 2021's advances in the treatment of esophageal/gastroesophageal junction cancers, particularly in locally advanced disease (CheckMate-577), metastatic HER2-negative disease (CheckMate-648, CheckMate-649, and KEYNOTE-590), and HER2-positive disease (KEYNOTE-811, DESTINY-Gastric-02), is presented.
Cancer , article en libre accès, 2022